Category Archives: Topics

Lilly Publishes TRIUMPH-1 and TRIUMPH-2 OSA Results; Abbott Q3 ’26 Earnings; Novo Wegovy Pill France Launch; ADA CSO/CMO Transition

A series of cardiometabolic-related news items has been observed from Lilly, Abbott, Novo, and ADA. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo REDEFINE 1 Post Hoc Analyses; Ascletis Preclinical QW Oral Peptide Data; Pfizer Berobenatide OSA Study; AZ/Oracle AI Partnership; Lilly/METiS LNP-Delivery Technology Partnership

A series of cardiometabolic-related news items has been observed from Novo, Ascletis Pharma, Pfizer, AstraZeneca/Oracle, and Lilly/METiS TechBio. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Merck Acquires Silence; Sanofi Insulin Manufacturing Expansion; Lilly Ph3 EloraTZP Pivotal Studies; Cytokinetics Myqorzo Health Canada Approval

A series of cardiometabolic-related news items has been observed from Merck KGaA, Sanofi, Lilly, and Cytokinetics. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

October CHMP Agenda Highlights; Pfizer Initiates Q3M Berobenatide Study; Novo Licenses New Drug Discovery Platform; Fractyl Shares 6-Month Revita Procedure Results; FDA Reaffirms Reta’s Classificaiton as a Drug; MiniMed Appoints Board; Sequel twiist AID Insulin-Treated T2DM FDA Clearance

A series of cardiometabolic-related news items has been observed from EMA, Pfizer, Novo/Ablexis, Fractyl Health, FDA/Lilly, MiniMed, and Sequel Med Tech. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novartis Terminates Ph3 Pelacarsen Studies; AZ Partners with insitro; Dexcom Publishes CONNECT RCT Results; Pfizer China-Based QM Berobenatide Obesity Study; Modular Medical Digital Learning Tool; Medtronic Finalizes MiniMed Separation; Atrogi Oral GRK2-Biased ß2-Adrenergic Modulator Data

A series of cardiometabolic-related news items has been observed from Novartis, AstraZeneca, Dexcom, Pfizer, Modular Medical, MiniMed, and Atrogi AB. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Verdiva Terminates Weekly Oral GLP-1RA Maintenance Study; Two Deaths Linked to Black Market Reta; Zealand Partners with Generate; Ultragenyx Sells Two PRVs; Amgen At-Home Autoinjector MariTide Study; iBio Preclinical Activin E Data; Biomea FIH BMF-650 Data; Caspian Menin Inhibitor Development Strategy

A series of cardiometabolic-related news items has been observed from Verdiva Bio, FDA, Zealand Pharma, Ultragenyx Pharmaceutical, Amgen, iBio, Biomea Fusion, and Caspian Therapeutics/Kura Oncology. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Rona Partners with Roche for ALK7-Targeting Asset; MetaVia Appoints New CMO; SAB-142 FDA Fast Track Designation

Three cardiometabolic-related news items have been observed: Rona Therapeutics entered into a partnership with Roche for an ALK7 asset to treat metabolic diseases (view press release); MetaVia appointed Sarah Browne as its new Chief Medical Officer (view press release); and SAB Bio received FDA Fast Track designation for the development of SAB-142 in Stage 3 T1DM (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Insulet Omnipod Discover Launch; October CHMP Agenda

Two cardiometabolic-related news items have been observed: Insulet launched its Omnipod Discover platform in the US (view press release), and the CHMP agenda for this month’s meeting (October 12-15) has been released (view agenda). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Amgen T2DM Ph3 MariTide H2H vs. Sema Study; Oral VK2735 Ph3 Obesity Program; Ascensia Enters Another CGM Partnership

Three cardiometabolic-related news items have been observed: Amgen registered its Ph3 MARITIME-T2D-3 study evaluating MariTide H2H vs. injectable sema (view CT.gov record); Viking posted its Ph3 SUNRISE obesity program of oral VK2735 (SUNRISE 1 CT.gov record; SUNRISE 2 CT.gov record); and Ascensia entered into a commercial distribution partnership with Sava (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

MiniMed Initiates 16-day CGM Study; FDA Accepts Bayer’s Finerenone Non-T2DM CKD sNDA; Ribo Life Science Submits Ph1 Application for INHBE siRNA Obesity Study in EU

Three cardiometabolic-related news items have been observed: MiniMed has registered a new study of its next-gen extended-wear CGM, called Unity (view CT.gov record); FDA accepted Bayer’s sNDA for finerenone in non-T2DM CKD (view press release); and Suzhou Ribo Life Science submitted a Ph1 CTA in the EU for its INHBE siRNA in obesity (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here